Recent Updates
Recently added Catalysts
ELOX Positive Sentiment

Eloxx Pharmaceuticals Announces Publication of Phase 2a Exaluren Data in Nonsense Mutation Alport Syndrome in the Journal of Clinical Investigation

Key Takeaway: Eloxx Pharmaceuticals announced the publication of Phase 2a data for exaluren in treating nonsense mutation Alport syndrome. The study demonstrated increased collagen IV levels and improved podocyte morphology in all participants. Exaluren was well tolerated without serious adverse events, supporting the ongoing Phase 2b EXACT study.

Market Sentiment Analysis

POSITIVE FACTORS

  • First-in-human evidence of exaluren's effectiveness
  • Increased collagen IV abundance in kidney biopsies
  • No serious adverse events reported
  • Supports ongoing Phase 2b EXACT study

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+312%
120-day peak, hindsight
Typical move
31.6%
average across 3 past catalysts
Cash runway
~39 mo
Minimal dilution risk
Lead asset
ELX-02
Phase 2 · Alport Syndrome

Full Press Release Details

Eloxx Pharmaceuticals Announces Publication of Phase 2a Exaluren Data in Nonsense Mutation Alport Syndrome in the Journal of Clinical Investigation

November 18, 2026
Eloxx Pharmaceuticals Announces Publication of Phase 2a Exaluren Data in Nonsense Mutation Alport Syndrome in the Journal of Clinical Investigation Accessibility Statement Skip Navigation First-in-human evidence of exaluren-mediated readthrough of collagen IV in patients with nonsense mutation Alport syndromeKidney biopsies showed increased collagen IV abundance and partially improved podocyte morphology in all three participantsExaluren was well tolerated, with no serious adverse events, nephrotoxicity or ototoxicityPublished findings support the ongoing Phase 2b EXACT studyARLINGTON, Mass., Nov. 18, 2026 /PRNewswire/ — Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren…

Frequently Asked Questions

What is exaluren used for?

Exaluren is developed for treating nonsense mutation Alport syndrome.

What were the findings of the Phase 2a study?

The study showed increased collagen IV and improved podocyte morphology.

How was exaluren tolerated in the study?

Exaluren was well tolerated with no serious adverse events reported.

What is the next step after Phase 2a?

The findings support the ongoing Phase 2b EXACT study.

Last updated: Nov 18, 2026